Medpace Investors Opportunity to Lead Lawsuit

Robbins Geller Rudman & Dowd LLP announces class action lawsuit for Medpace stockholders with substantial losses.

Apr. 11, 2026 at 8:39pm

Got story updates? Submit your updates here. ›

A photorealistic studio still-life featuring a stack of financial documents, a calculator, and a gavel on a clean, monochromatic background, conceptually representing the abstract legal and financial issues at the heart of this investor lawsuit.A legal case alleging financial misconduct at a major clinical research firm offers investors a chance to recoup substantial losses.San Diego Today

The law firm of Robbins Geller Rudman & Dowd LLP has announced that purchasers or acquirers of Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026 have until June 8, 2026 to seek appointment as lead plaintiffs in a class action lawsuit against the company.

Why it matters

Medpace is a clinical research organization that provides services to the pharmaceutical, biotechnology, and medical device industries. The class action lawsuit alleges that the company made false and misleading statements during the class period, which resulted in substantial losses for investors.

The details

The lawsuit claims that Medpace failed to disclose material information about the company's business, operations, and prospects, leading to an inflated stock price. Investors who purchased Medpace stock during the class period and suffered significant losses are now eligible to join the class action lawsuit and potentially recover their losses.

  • The class period is from April 22, 2025 to February 9, 2026.
  • The deadline to seek appointment as lead plaintiffs is June 8, 2026.

The players

Robbins Geller Rudman & Dowd LLP

A law firm that specializes in class action lawsuits and represents investors who have suffered substantial losses.

Medpace Holdings Inc.

A clinical research organization that provides services to the pharmaceutical, biotechnology, and medical device industries.

Got photos? Submit your photos here. ›

What’s next

Investors who purchased Medpace stock during the class period and suffered significant losses have until June 8, 2026 to seek appointment as lead plaintiffs in the class action lawsuit.

The takeaway

This case highlights the importance of transparency and accurate disclosure in the financial markets, as well as the legal recourse available to investors who have suffered substantial losses due to alleged corporate misconduct.